Imperial College London

Dr Alethea Cope (PhD)

Faculty of MedicineDepartment of Infectious Disease

Honorary Senior Research Fellow



+44 (0)20 3315 5098a.cope




Human Immunology Lab (IAVI-HIL)Chelsea and Westminster HospitalChelsea and Westminster Campus





Senior Director Human Immunology – IAVI HIL, Honorary Senior Research Fellow Imperial College London

Responsible for strategic and scientific leadership of the IAVI-HIL based at Chelsea and Westminster Campus London,
Leading infectious diseases vaccine and monoclonal antibody programs for; HIV, TB, malaria and emerging infectious diseases (EIDs) including COVID. Responsible for management of a team of scientists, research staff and operations at IAVI-HIL. 

I have over 20 years’ post-doctoral experience working primarily in the academic sector in the UK since gaining my PhD in 1998.  My early career was spent establishing myself as a bench scientist developing my skills as a virologist and immunologist. Later I became more interested in translational science and how to transition basic science from bench to bedside. My career has been spent primarily in the university sector at three London universities intimately linked to biomedical research and NHS clinical research centers. Mostly I have led scientifically and strategically on projects related to understanding human disease, primarily infectious diseases and prevention strategy solutions including vaccine programs. More recently I have worked across rare diseases, genetic disorders and emerging infectious diseases including COVID. I have successfully led large multi-stakeholder projects from conception to pre-clinical stage and ultimately through to evaluation in clinical trials.  At UCL I secured funding from the MRC, Wellcome Trust, Innovate UK, CRUK to support a diverse portfolio of translational projects outside of my own area of expertise. I consider myself well versed in aligning, acquiring and implementing appropriate funding streams across the academic sector for translational science to ultimately improve health. My true passion lies in finding solutions to complex problems collaboratively while taking forward excellent science for the benefit of human health.

Useful Links:




Haidari G, Day S, Wood M, et al., 2019, The safety and immunogenicity of GTU (R) MultiHIV DNA vaccine delivered by transcutaneous and intramuscular injection with or without electroporation in HIV-1 positive subjects on suppressive ART, Frontiers in Immunology, Vol:10, ISSN:1664-3224, Pages:1-8

Nadai Y, Held K, Joseph S, et al., 2019, Envelope-specific recognition patterns of HIV vaccine-induced IgG antibodies are linked to immunogen structure and sequence, Frontiers in Immunology, Vol:10, ISSN:1664-3224, Pages:1-14

Tran MGB, Neves JB, Stamati K, et al., 2019, Acceptability and feasibility study of patient-specific 'tumouroids' as personalised treatment screening tools: Protocol for prospective tissue and data collection of participants with confirmed or suspected renal cell carcinoma., Int J Surg Protoc, Vol:14, Pages:24-29

Cheeseman HM, Day S, McFarlane LR, et al., 2018, Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine, Human Gene Therapy, Vol:29, ISSN:1043-0342, Pages:1011-1028


Cheeseman H, Day S, McFarlane L, et al., 2018, Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to an HIV-1 Clade C Envelope Vaccine, HIV Research for Prevention Meeting (HIVR4P) - AIDS Vaccine, Microbicide and ARV-Based Prevention Science, MARY ANN LIEBERT, INC, Pages:43-43, ISSN:0889-2229

More Publications